医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Research and Markets: Irritable Bowel Syndrome (Event Driven)

2012年09月26日 AM02:01
このエントリーをはてなブックマークに追加


 

DUBLIN

Research and Markets (http://www.researchandmarkets.com/research/6tdpwp/irritable_bowel) has announced the addition of Decision Resources, Inc’s new report “Irritable Bowel Syndrome (Event Driven)” to their offering.

Although a highly prevalent condition, irritable bowel syndrome (IBS) is marked by low diagnosis and treatment rates in the major pharmaceutical markets under study. Many patients self-medicate with OTC products, and many of the prescription drugs available to treat diagnosed patients offer suboptimal efficacy and side-effect profiles. Considerable commercial potential is available to companies that can develop and promote safe, effective therapies for this underserved and highly genericized market. Because of their premium prices, the launch of a few novel therapies will more than triple major-market IBS sales during our ten-year forecast period.

Key Topics Covered:

– Executive Summary

– 1 Etiology and Pathophysiology

– 2 Epidemiology and Patient Populations

– 3 Current Therapies and Medical Practice

– 4 Unmet Needs

– 5 Emerging Therapies

– 6 Market Outlook

– Appendix A Bibliography-Irritable Bowel Syndrome

– Appendix B Market Forecast Methodology

– Appendix C Experts InterviewedIrritable Bowel Syndrome

– Appendix D Supplemental Epidemiology Bibliography

– Tables and Figures

For more information visit http://www.researchandmarkets.com/research/6tdpwp/irritable_bowel

Source: Decision Resources, Inc

CONTACT

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare
and Medical Devices
, Pharmaceuticals

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 2023年扎耶德可持续发展奖持续彰显全球影响力,收获超4,500份申请
  • ザーイド・サステナビリティ賞2023年度の応募を締切り、最終応募数は4,500件超に!
  • U.S. Alliance Pharma Expands Early Phase Bioanalytical Services Into Australia
  • Avivagen Announces Receipt of Repeat Order from Asian Customer
  • フェリングが微生物叢ベースのライブバイオ治療薬RBX2660に関する米国FDA諮問委員会会議の開催を発表